Sidley Austin LLP served as legal advisor to Carlin and Wilson Sonsini Goodrich Rosati acted as legal advisor to Infirst. Stifel acted as exclusive financial advisor...
Carlin Consumer Health’s Acquisition of Infirst USA Holdings
Pyxis Oncology’s Acquisition of Apexigen
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
Akeso’s US$5 Billion Licensing Agreement With Summit Therapeutics Title
Sidley advised Akeso Inc. on the deal. Akeso Inc. announced a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific...
Yisheng Biopharma Co., Ltd.’s US$40 Million Royalty-Backed Financing From R-Bridge Healthcare Fund
Clifford Chance has advised Yisheng Biopharma Co., Ltd. on the deal, while Sidley Austin LLP and Maples and Calder advised R-Bridge Healthcare Fund. Yisheng Biopharma Co.,...
Tyra Biosciences’ $172.8 Million Initial Public Offering
Latham & Watkins represented Tyra Biosciences in the offering while Sidley advised the underwriters. Tyra Biosciences, Inc. has announced the pricing of its upsized initial public offering of...
Interius BioTherapeutics’ US$76 Million Series A financing.
Sidley Austin LLP advised Interius BioTherapeutics on the deal. Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene...
Tempest Therapeutics’ Merger With Millendo Therapeutics
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...
Tempest Therapeutics’ Merger With Millendo Therapeutics
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...